Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Brentuximab Vedotin |
ADC | Hematologic | ||
|
Molecule
Brentuximab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Gemtuzumab Ozogamicin |
ADC | Hematologic | ||
|
Molecule
Gemtuzumab Ozogamicin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Inotuzumab Ozogamicin |
ADC | Hematologic | ||
|
Molecule
Inotuzumab Ozogamicin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Polatuzumab Vedotin |
ADC | Hematologic | ||
|
Molecule
Polatuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Loncastuximab Tesirine |
ADC | Hematologic | ||
|
Molecule
Loncastuximab Tesirine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Belantamab Mafodotin |
ADC | Hematologic | ||
|
Molecule
Belantamab Mafodotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Tafasitamab |
ADC | Hematologic | ||
|
Molecule
Tafasitamab
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Naratuximab Emtansine |
ADC | Hematologic | ||
|
Molecule
Naratuximab Emtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Sacituzumab Govitecan |
ADC | Solid Tumour | ||
|
Molecule
Sacituzumab Govitecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Enfortumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Enfortumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Tisotumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Tisotumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Mirvetuximab Soravtansine |
ADC | Solid Tumour | ||
|
Molecule
Mirvetuximab Soravtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Brentuximab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Gemtuzumab OzogamicinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Inotuzumab OzogamicinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Polatuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Loncastuximab TesirineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Belantamab MafodotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
TafasitamabTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Naratuximab EmtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Sacituzumab GovitecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Enfortumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Tisotumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Mirvetuximab SoravtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|

